Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 8/20 | 0.46 |
| ▸ | MAOB | P27338 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PDE5A | O76074 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | TNKS | O95271 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163625 | 0.85 | LMNA (0.51) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL2419303 | 0.81 | LMNA (0.48) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL15724892 | 0.80 | LMNA (0.50) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL503654 | 0.79 | SIGMAR1 (0.57) | LMNAGAACYP19A1MAOBKDM4E | |
| SCHEMBL1207853 | 0.78 | SIGMAR1 (0.56) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL6461145 | 0.78 | SIGMAR1 (0.53) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL13485788 | 0.76 | PDE5A (0.67) | LMNAGAACYP19A1KDM4EALDH1A1 | |
| SCHEMBL5266396 | 0.75 | KDM4E (0.56) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL1893563 | 0.74 | GAA (0.52) | LMNAGAACYP19A1MAOBCYP3A4 | |
| SCHEMBL22319274 | 0.74 | GAA (0.52) | LMNAGAACYP19A1MAOBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0758021-B1 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA SPA (IT) | 2006-03-29 | — | — | EP | claimed |
| US-6057297-A | ANTAGONIZE LETHAL EFFECTS OF CERTAIN CLASSES OF SNAKE VENOM | POLIFARMA S.P.A. (IT) | 2000-05-02 | — | — | US | claimed |
| US-5846755-A | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds | POLIFARMA S.P.A. (IT) | 1998-12-08 | — | — | US | claimed |
| EP-0758021-A2 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA S.p.A. (IT) | 1997-02-12 | — | — | EP | claimed |
| EP-0758021-B1 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA SPA (IT) | 2006-03-29 | — | — | EP | disclosed |
| US-6057297-A | ANTAGONIZE LETHAL EFFECTS OF CERTAIN CLASSES OF SNAKE VENOM | POLIFARMA S.P.A. (IT) | 2000-05-02 | — | — | US | disclosed |
| US-5846755-A | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds | POLIFARMA S.P.A. (IT) | 1998-12-08 | — | — | US | disclosed |
| EP-0758021-A2 | Method for determining the therapeutic activity of metalloproteinase inhibitor compounds, new inhibitor compounds, and the therapeutic use thereof | POLIFARMA S.p.A. (IT) | 1997-02-12 | — | — | EP | disclosed |